Aeterna Zentaris sees rise in Q2 revenues

The increase is related to comparative higher-than-normal deliveries of Cetrotide to certain customers, as well as to the comparative strengthening of the euro against the US dollar.

The company has posted a net loss of $10.57m for the second quarter of 2011, compared to $6.18m for the same period in 2010.

The company’s loss from operations were $7.97m, compared to $7.95m for the same period prior year.

For the six months ended 30 June 2011, the company reported revenues of $13.91m, compared to $12.01m for the same period in 2010.

Aeterna has reported net loss of $20.63m for the six months ended 30 June 2011, compared to $11.92m for the same period in 2010.

For the six months ended 30 June 2011, the company’s loss form operations were $15.26m, compared to $15.35m for the same period prior year.